BR112015010875B1 - Compostos de n-pirrolidinil, n-pirazolil-ureia, tioureia, guanidina e cianoguanidina como inibidores de trka quinase, sua composição farmacêutica, seu uso e seu processo para preparação - Google Patents

Info

Publication number

BR112015010875B1

BR112015010875B1 BR112015010875-0A BR112015010875A BR112015010875B1 BR 112015010875 B1 BR112015010875 B1 BR 112015010875B1 BR 112015010875 A BR112015010875 A BR 112015010875A BR 112015010875 B1 BR112015010875 B1 BR 112015010875B1

Authority

BR

Brazil

Prior art keywords

alkyl

formula

compound

pain

mmol

Prior art date

2012-11-13

Links

• Espacenet
• Global Dossier
• Discuss

• 238000002360 preparation method Methods 0.000 title claims abstract description 135
• 238000000034 method Methods 0.000 title claims abstract description 77
• 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
• 230000008569 process Effects 0.000 title claims abstract description 8
• -1 N-PYRROLIDINYL Chemical class 0.000 title abstract description 99
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract description 37
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 title abstract description 8
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 title abstract description 8
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 title abstract description 4
• QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical class NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 title abstract description 4
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 title abstract description 4
• 229940043355 kinase inhibitor Drugs 0.000 title abstract 4
• 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 4
• XAEGRAIWWBXIRR-UHFFFAOYSA-N 1h-pyrazol-5-ylurea Chemical compound NC(=O)NC=1C=CNN=1 XAEGRAIWWBXIRR-UHFFFAOYSA-N 0.000 title abstract 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 259
• 208000002193 Pain Diseases 0.000 claims abstract description 88
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 64
• 201000011510 cancer Diseases 0.000 claims abstract description 54
• 150000003839 salts Chemical class 0.000 claims abstract description 54
• 238000011282 treatment Methods 0.000 claims abstract description 34
• 230000004770 neurodegeneration Effects 0.000 claims abstract description 18
• 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 18
• 206010061218 Inflammation Diseases 0.000 claims abstract description 16
• 208000027866 inflammatory disease Diseases 0.000 claims abstract description 16
• 208000011580 syndromic disease Diseases 0.000 claims abstract description 16
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims abstract description 15
• 201000009273 Endometriosis Diseases 0.000 claims abstract description 15
• 208000000450 Pelvic Pain Diseases 0.000 claims abstract description 15
• 230000004054 inflammatory process Effects 0.000 claims abstract description 15
• 201000007094 prostatitis Diseases 0.000 claims abstract description 15
• 208000021386 Sjogren Syndrome Diseases 0.000 claims abstract description 14
• 208000035473 Communicable disease Diseases 0.000 claims abstract description 12
• 239000012453 solvate Substances 0.000 claims abstract description 7
• 125000000217 alkyl group Chemical group 0.000 claims description 363
• 125000003545 alkoxy group Chemical group 0.000 claims description 83
• 229910052736 halogen Inorganic materials 0.000 claims description 60
• 150000002367 halogens Chemical class 0.000 claims description 60
• 239000003814 drug Substances 0.000 claims description 45
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
• 125000001424 substituent group Chemical group 0.000 claims description 40
• 125000001153 fluoro group Chemical group F* 0.000 claims description 37
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
• 235000019000 fluorine Nutrition 0.000 claims description 36
• 208000000094 Chronic Pain Diseases 0.000 claims description 15
• 238000002560 therapeutic procedure Methods 0.000 claims description 14
• 208000005298 acute pain Diseases 0.000 claims description 13
• 208000004296 neuralgia Diseases 0.000 claims description 12
• 208000021722 neuropathic pain Diseases 0.000 claims description 12
• 208000010392 Bone Fractures Diseases 0.000 claims description 11
• 206010065390 Inflammatory pain Diseases 0.000 claims description 11
• 238000001356 surgical procedure Methods 0.000 claims description 11
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 9
• 230000008878 coupling Effects 0.000 claims description 7
• 238000010168 coupling process Methods 0.000 claims description 7
• 238000005859 coupling reaction Methods 0.000 claims description 7
• 125000006239 protecting group Chemical group 0.000 claims description 7
• 230000002757 inflammatory effect Effects 0.000 claims description 6
• 229910052740 iodine Inorganic materials 0.000 claims description 6
• 206010009944 Colon cancer Diseases 0.000 claims description 5
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
• 206010029260 Neuroblastoma Diseases 0.000 claims description 5
• 206010060862 Prostate cancer Diseases 0.000 claims description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
• 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 208000010749 gastric carcinoma Diseases 0.000 claims description 4
• 208000005017 glioblastoma Diseases 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 229910052763 palladium Inorganic materials 0.000 claims description 4
• 201000000498 stomach carcinoma Diseases 0.000 claims description 4
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
• 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
• 239000003054 catalyst Substances 0.000 claims description 3
• 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
• MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims description 3
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 2
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 2
• 150000002148 esters Chemical class 0.000 claims description 2
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
• 125000005843 halogen group Chemical group 0.000 claims 2
• 230000003213 activating effect Effects 0.000 claims 1
• 101150111783 NTRK1 gene Proteins 0.000 abstract description 49
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 41
• 201000010099 disease Diseases 0.000 abstract description 31
• 229940002612 prodrug Drugs 0.000 abstract description 3
• 239000000651 prodrug Substances 0.000 abstract description 3
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 162
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 156
• 239000000203 mixture Substances 0.000 description 110
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 109
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 103
• 239000000243 solution Substances 0.000 description 63
• 239000007787 solid Substances 0.000 description 62
• 241000124008 Mammalia Species 0.000 description 57
• 235000019439 ethyl acetate Nutrition 0.000 description 54
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 48
• 239000000377 silicon dioxide Substances 0.000 description 48
• 238000004440 column chromatography Methods 0.000 description 47
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 46
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
• 239000012267 brine Substances 0.000 description 32
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 32
• 229940124597 therapeutic agent Drugs 0.000 description 28
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
• 125000004432 carbon atom Chemical group C* 0.000 description 27
• 239000010410 layer Substances 0.000 description 27
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 27
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
• 239000002585 base Substances 0.000 description 26
• 239000011541 reaction mixture Substances 0.000 description 24
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 23
• 239000013058 crude material Substances 0.000 description 23
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 23
• 235000019341 magnesium sulphate Nutrition 0.000 description 23
• 229920006395 saturated elastomer Polymers 0.000 description 23
• 239000007832 Na2SO4 Substances 0.000 description 22
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
• 239000003112 inhibitor Substances 0.000 description 22
• 229910052938 sodium sulfate Inorganic materials 0.000 description 22
• 235000011152 sodium sulphate Nutrition 0.000 description 22
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 21
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 21
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 20
• 238000006243 chemical reaction Methods 0.000 description 19
• 239000000725 suspension Substances 0.000 description 19
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
• 239000004202 carbamide Substances 0.000 description 17
• 239000000706 filtrate Substances 0.000 description 17
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 17
• 125000005842 heteroatom Chemical group 0.000 description 16
• ZMCGJMHVCOACEF-GXFFZTMASA-N (3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=C(F)C(F)=C1 ZMCGJMHVCOACEF-GXFFZTMASA-N 0.000 description 15
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
• 239000012074 organic phase Substances 0.000 description 15
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 14
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 14
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 14
• MZUSCPDSQJSBSY-UHFFFAOYSA-N (6-methylpyridin-3-yl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=N1 MZUSCPDSQJSBSY-UHFFFAOYSA-N 0.000 description 13
• 108010025020 Nerve Growth Factor Proteins 0.000 description 13
• 239000003795 chemical substances by application Substances 0.000 description 13
• 239000003921 oil Substances 0.000 description 13
• 235000019198 oils Nutrition 0.000 description 13
• 239000012044 organic layer Substances 0.000 description 13
• 108091000080 Phosphotransferase Proteins 0.000 description 12
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
• PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 12
• 102000020233 phosphotransferase Human genes 0.000 description 12
• 239000000047 product Substances 0.000 description 12
• 150000003254 radicals Chemical class 0.000 description 12
• 239000002904 solvent Substances 0.000 description 12
• 229910052717 sulfur Inorganic materials 0.000 description 12
• 239000004215 Carbon black (E152) Substances 0.000 description 11
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
• 230000008482 dysregulation Effects 0.000 description 11
• 229930195733 hydrocarbon Natural products 0.000 description 11
• 229910052739 hydrogen Inorganic materials 0.000 description 11
• 229910052760 oxygen Inorganic materials 0.000 description 11
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 10
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
• 208000005615 Interstitial Cystitis Diseases 0.000 description 10
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
• 125000004093 cyano group Chemical group *C#N 0.000 description 10
• 208000035475 disorder Diseases 0.000 description 10
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
• 239000006188 syrup Substances 0.000 description 10
• 235000020357 syrup Nutrition 0.000 description 10
• 238000005160 1H NMR spectroscopy Methods 0.000 description 9
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
• 206010027452 Metastases to bone Diseases 0.000 description 9
• 102000015336 Nerve Growth Factor Human genes 0.000 description 9
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 9
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 9
• 239000000284 extract Substances 0.000 description 9
• 125000000623 heterocyclic group Chemical group 0.000 description 9
• 239000000543 intermediate Substances 0.000 description 9
• 229940053128 nerve growth factor Drugs 0.000 description 9
• 229910000027 potassium carbonate Inorganic materials 0.000 description 9
• 239000000843 powder Substances 0.000 description 9
• QTQZQIYWGIQHHR-QWHCGFSZSA-N (3s,4r)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=C(F)C=C1 QTQZQIYWGIQHHR-QWHCGFSZSA-N 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 8
• 239000001257 hydrogen Substances 0.000 description 8
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
• 229910052757 nitrogen Inorganic materials 0.000 description 8
• 235000015320 potassium carbonate Nutrition 0.000 description 8
• 238000003756 stirring Methods 0.000 description 8
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 7
• 208000024699 Chagas disease Diseases 0.000 description 7
• 208000001132 Osteoporosis Diseases 0.000 description 7
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 7
• 229940043279 diisopropylamine Drugs 0.000 description 7
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
• 229910052731 fluorine Inorganic materials 0.000 description 7
• 229960005181 morphine Drugs 0.000 description 7
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 description 7
• 125000003396 thiol group Chemical group [H]S* 0.000 description 7
• IWWQROMVQSKLDE-UHFFFAOYSA-N 2-methoxy-n-(methoxymethyl)-n-(trimethylsilylmethyl)ethanamine Chemical compound COCCN(COC)C[Si](C)(C)C IWWQROMVQSKLDE-UHFFFAOYSA-N 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 6
• 125000004414 alkyl thio group Chemical group 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 230000001684 chronic effect Effects 0.000 description 6
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
• 239000011521 glass Substances 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
• 229930195734 saturated hydrocarbon Natural products 0.000 description 6
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 6
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 5
• 206010001935 American trypanosomiasis Diseases 0.000 description 5
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 5
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 5
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 5
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
• 229960001138 acetylsalicylic acid Drugs 0.000 description 5
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
• 125000003368 amide group Chemical group 0.000 description 5
• 229940035676 analgesics Drugs 0.000 description 5
• 239000000730 antalgic agent Substances 0.000 description 5
• 230000003110 anti-inflammatory effect Effects 0.000 description 5
• 229910052786 argon Inorganic materials 0.000 description 5
• 229910052801 chlorine Inorganic materials 0.000 description 5
• 229910052681 coesite Inorganic materials 0.000 description 5
• 229960004544 cortisone Drugs 0.000 description 5
• 229910052906 cristobalite Inorganic materials 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 229960003957 dexamethasone Drugs 0.000 description 5
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 238000010828 elution Methods 0.000 description 5
• 229960002714 fluticasone Drugs 0.000 description 5
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 5
• 125000001072 heteroaryl group Chemical group 0.000 description 5
• ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 5
• 229960001680 ibuprofen Drugs 0.000 description 5
• 229960000905 indomethacin Drugs 0.000 description 5
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 5
• 229960000991 ketoprofen Drugs 0.000 description 5
• 229940005483 opioid analgesics Drugs 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 125000004076 pyridyl group Chemical group 0.000 description 5
• 238000010992 reflux Methods 0.000 description 5
• 235000012239 silicon dioxide Nutrition 0.000 description 5
• 150000003431 steroids Chemical class 0.000 description 5
• 229910052682 stishovite Inorganic materials 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 229910052905 tridymite Inorganic materials 0.000 description 5
• AWFLFCUEMZCTSP-QWHCGFSZSA-N (3r,4s)-3-(4-fluorophenyl)-1-(2-methoxyethyl)-4-nitropyrrolidine Chemical compound [O-][N+](=O)[C@@H]1CN(CCOC)C[C@H]1C1=CC=C(F)C=C1 AWFLFCUEMZCTSP-QWHCGFSZSA-N 0.000 description 4
• QREMSDXRGJWNST-QWHCGFSZSA-N (3s,4r)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC(F)=CC(F)=C1 QREMSDXRGJWNST-QWHCGFSZSA-N 0.000 description 4
• GRZLJCLJVRXLLP-GXFFZTMASA-N (3s,4r)-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=C(F)C(Cl)=C1 GRZLJCLJVRXLLP-GXFFZTMASA-N 0.000 description 4
• ZTVHJKAWOVGJTF-CQSOCPNPSA-N (3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=CC(F)=C1 ZTVHJKAWOVGJTF-CQSOCPNPSA-N 0.000 description 4
• RJIDSVJDKGCEFC-UHFFFAOYSA-N (5-amino-4-methyl-1-phenylpyrazol-3-yl) trifluoromethanesulfonate Chemical compound NC1=C(C)C(OS(=O)(=O)C(F)(F)F)=NN1C1=CC=CC=C1 RJIDSVJDKGCEFC-UHFFFAOYSA-N 0.000 description 4
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
• VRFSQVFSQAYHRU-AATRIKPKSA-N 1-fluoro-4-[(e)-2-nitroethenyl]benzene Chemical compound [O-][N+](=O)\C=C\C1=CC=C(F)C=C1 VRFSQVFSQAYHRU-AATRIKPKSA-N 0.000 description 4
• IUURCNSBVAESQR-UHFFFAOYSA-N 3-amino-4-methyl-2-phenyl-1h-pyrazol-5-one Chemical compound N1C(=O)C(C)=C(N)N1C1=CC=CC=C1 IUURCNSBVAESQR-UHFFFAOYSA-N 0.000 description 4
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 4
• UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 4
• IXLVUUFUDRJUSL-RPBOFIJWSA-N 5-[[4-(3-acetamidophenyl)phenyl]methyl]-n-[(1s,2r)-2-phenylcyclopropyl]-1,3-oxazole-4-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2C=CC(CC3=C(N=CO3)C(=O)N[C@@H]3[C@H](C3)C=3C=CC=CC=3)=CC=2)=C1 IXLVUUFUDRJUSL-RPBOFIJWSA-N 0.000 description 4
• KKRHOLKYEHISDV-UHFFFAOYSA-N 5-bromo-4-methyl-2-phenylpyrazol-3-amine Chemical compound NC1=C(C)C(Br)=NN1C1=CC=CC=C1 KKRHOLKYEHISDV-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• 206010012438 Dermatitis atopic Diseases 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 108010008165 Etanercept Proteins 0.000 description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
• 102000007072 Nerve Growth Factors Human genes 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• 239000008346 aqueous phase Substances 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• 201000008937 atopic dermatitis Diseases 0.000 description 4
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
• 125000002837 carbocyclic group Chemical group 0.000 description 4
• 239000006071 cream Substances 0.000 description 4
• 208000037765 diseases and disorders Diseases 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 239000006260 foam Substances 0.000 description 4
• 108020001507 fusion proteins Proteins 0.000 description 4
• 102000037865 fusion proteins Human genes 0.000 description 4
• 239000007789 gas Substances 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 229960000485 methotrexate Drugs 0.000 description 4
• AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 230000026749 regulation of bone remodeling Effects 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• YJOOGAYDRUKEAZ-QWHCGFSZSA-N tert-butyl n-[(3s,4r)-4-[3-(trifluoromethyl)phenyl]pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CNC[C@H]1C1=CC=CC(C(F)(F)F)=C1 YJOOGAYDRUKEAZ-QWHCGFSZSA-N 0.000 description 4
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
• 239000011701 zinc Substances 0.000 description 4
• XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 3
• NTOIKDYVJIWVSU-WOJBJXKFSA-N (2r,3r)-2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-WOJBJXKFSA-N 0.000 description 3
• IGWKPIIVNXZWMT-VHSXEESVSA-N (3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxylic acid Chemical compound COCCN1C[C@H]([C@@H](C1)c1cc(F)c(F)c(F)c1)C(O)=O IGWKPIIVNXZWMT-VHSXEESVSA-N 0.000 description 3
• PTYOOBMZMFYKKB-FAJLARSSSA-N (3s,4r)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC(F)=C(F)C(F)=C1 PTYOOBMZMFYKKB-FAJLARSSSA-N 0.000 description 3
• PHRNRZZMLWTRDB-CQSOCPNPSA-N (3s,4r)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=CC=C1 PHRNRZZMLWTRDB-CQSOCPNPSA-N 0.000 description 3
• WXBOUFZFJFRVCW-DLBZAZTESA-N (3s,4r)-1-benzyl-4-phenylpyrrolidin-3-amine Chemical compound C([C@H]([C@@H](C1)C=2C=CC=CC=2)N)N1CC1=CC=CC=C1 WXBOUFZFJFRVCW-DLBZAZTESA-N 0.000 description 3
• NXJMLAYANQKFJH-QKLQHJQFSA-N (4R)-3-[(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carbonyl]-4-phenyl-1,3-oxazolidin-2-one Chemical compound COCCN1C[C@H]([C@@H](C1)C1=CC(=C(C(=C1)F)F)F)C(=O)N1C(OC[C@H]1C1=CC=CC=C1)=O NXJMLAYANQKFJH-QKLQHJQFSA-N 0.000 description 3
• UJTJVEMQVWUKCS-HNNXBMFYSA-N (4R)-4-phenyl-3-[(E)-3-(3,4,5-trifluorophenyl)prop-2-enoyl]-1,3-oxazolidin-2-one Chemical compound C1(=CC=CC=C1)[C@H]1N(C(OC1)=O)C(C=CC1=CC(=C(C(=C1)F)F)F)=O UJTJVEMQVWUKCS-HNNXBMFYSA-N 0.000 description 3
• QDMNNMIOWVJVLY-QMMMGPOBSA-N (4r)-4-phenyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@@H]1C1=CC=CC=C1 QDMNNMIOWVJVLY-QMMMGPOBSA-N 0.000 description 3
• RJNZUERQMGKTAF-INIZCTEOSA-N (4r)-4-phenyl-3-(3-phenylprop-2-enoyl)-1,3-oxazolidin-2-one Chemical compound C([C@H]1C=2C=CC=CC=2)OC(=O)N1C(=O)C=CC1=CC=CC=C1 RJNZUERQMGKTAF-INIZCTEOSA-N 0.000 description 3
• FMIXMIIQMWKVLQ-OWOJBTEDSA-N (e)-3-(3,4,5-trifluorophenyl)prop-2-enoyl chloride Chemical compound FC1=CC(\C=C\C(Cl)=O)=CC(F)=C1F FMIXMIIQMWKVLQ-OWOJBTEDSA-N 0.000 description 3
• WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 3
• WYLZKEAKTKRGKT-UHFFFAOYSA-N 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-one Chemical compound CN1C(=O)C(C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 WYLZKEAKTKRGKT-UHFFFAOYSA-N 0.000 description 3
• GWTDXPQBXSUNSH-GHTZIAJQSA-N 1-(5-bromo-4-methyl-2-phenylpyrazol-3-yl)-3-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(Br)=NN1C1=CC=CC=C1 GWTDXPQBXSUNSH-GHTZIAJQSA-N 0.000 description 3
• YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 3
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 3
• IXGAHBAKWGXVLG-UHFFFAOYSA-N 4-methyl-5-(6-methylpyridin-3-yl)-2-phenylpyrazol-3-amine Chemical compound CC1=C(N)N(C=2C=CC=CC=2)N=C1C1=CC=C(C)N=C1 IXGAHBAKWGXVLG-UHFFFAOYSA-N 0.000 description 3
• CQYRYBXTWCXMAX-UHFFFAOYSA-N 4-methyl-5-methylsulfonyl-2-phenylpyrazol-3-amine Chemical compound N1=C(S(C)(=O)=O)C(C)=C(N)N1C1=CC=CC=C1 CQYRYBXTWCXMAX-UHFFFAOYSA-N 0.000 description 3
• ILAIFMQMPGUFTC-UHFFFAOYSA-N 5-(5-amino-4-methyl-1-phenylpyrazol-3-yl)-1,3-dimethylpyridin-2-one Chemical compound CC1=C(N)N(C=2C=CC=CC=2)N=C1C=1C=C(C)C(=O)N(C)C=1 ILAIFMQMPGUFTC-UHFFFAOYSA-N 0.000 description 3
• BCONSDJEHRFYFF-UHFFFAOYSA-N 5-(5-amino-4-methyl-1-phenylpyrazol-3-yl)-1-methylpyridin-2-one Chemical compound CC1=C(N)N(C=2C=CC=CC=2)N=C1C=1C=CC(=O)N(C)C=1 BCONSDJEHRFYFF-UHFFFAOYSA-N 0.000 description 3
• AXPXVAAVEQJUCA-UHFFFAOYSA-N 5-(5-amino-4-methyl-1-phenylpyrazol-3-yl)-1-methylpyrimidin-2-one Chemical compound CC1=C(N)N(C=2C=CC=CC=2)N=C1C=1C=NC(=O)N(C)C=1 AXPXVAAVEQJUCA-UHFFFAOYSA-N 0.000 description 3
• GXWBLPVKFBEOMR-GXTWGEPZSA-N 5-[(3r,4s)-4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl]-2-fluorobenzonitrile Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=C(F)C(C#N)=C1 GXWBLPVKFBEOMR-GXTWGEPZSA-N 0.000 description 3
• ZVRLVTVCMHRKMG-UHFFFAOYSA-N 5-amino-n-methoxy-n,4-dimethyl-1-phenylpyrazole-3-carboxamide Chemical compound NC1=C(C)C(C(=O)N(C)OC)=NN1C1=CC=CC=C1 ZVRLVTVCMHRKMG-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• XSOMFHWEUCMWFT-QFBILLFUSA-N COCCN1C[C@H]([C@@H](C1)C1=CC(=C(C(=C1)F)F)F)NC(OCC1=CC=CC=C1)=O Chemical compound COCCN1C[C@H]([C@@H](C1)C1=CC(=C(C(=C1)F)F)F)NC(OCC1=CC=CC=C1)=O XSOMFHWEUCMWFT-QFBILLFUSA-N 0.000 description 3
• DPMMOHOSVYAMTP-UHFFFAOYSA-N Cc1c(NC(=O)Oc2ccccc2)n(nc1S(C)(=O)=O)-c1ccccc1 Chemical compound Cc1c(NC(=O)Oc2ccccc2)n(nc1S(C)(=O)=O)-c1ccccc1 DPMMOHOSVYAMTP-UHFFFAOYSA-N 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 206010011796 Cystitis interstitial Diseases 0.000 description 3
• DXVVCCGGVHQVGV-JKSUJKDBSA-N FC=1C=C(C=CC1)[C@H]1[C@@H](CN(C1)CCOC)NC(OC(C)(C)C)=O Chemical compound FC=1C=C(C=CC1)[C@H]1[C@@H](CN(C1)CCOC)NC(OC(C)(C)C)=O DXVVCCGGVHQVGV-JKSUJKDBSA-N 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
• 239000007868 Raney catalyst Substances 0.000 description 3
• 229910000564 Raney nickel Inorganic materials 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 238000011374 additional therapy Methods 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 235000011114 ammonium hydroxide Nutrition 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 238000001816 cooling Methods 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 230000000694 effects Effects 0.000 description 3
• DOHIIYWAVNJMJZ-UHFFFAOYSA-N ethyl 3-cyano-2-oxobutanoate Chemical compound CCOC(=O)C(=O)C(C)C#N DOHIIYWAVNJMJZ-UHFFFAOYSA-N 0.000 description 3
• RZWXEKKSMFXYJR-UHFFFAOYSA-N ethyl 5-amino-4-methyl-1-phenylpyrazole-3-carboxylate Chemical compound NC1=C(C)C(C(=O)OCC)=NN1C1=CC=CC=C1 RZWXEKKSMFXYJR-UHFFFAOYSA-N 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000014509 gene expression Effects 0.000 description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 125000000842 isoxazolyl group Chemical group 0.000 description 3
• YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 3
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 125000002971 oxazolyl group Chemical group 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• MZESFRKCTLGKSF-UHFFFAOYSA-N phenyl N-(5-bromo-4-methyl-2-phenylpyrazol-3-yl)carbamate Chemical compound Cc1c(Br)nn(c1NC(=O)Oc1ccccc1)-c1ccccc1 MZESFRKCTLGKSF-UHFFFAOYSA-N 0.000 description 3
• GBVSBTLEIACECG-UHFFFAOYSA-N phenyl n-[4-methyl-5-(1-methyl-6-oxopyridin-3-yl)-2-phenylpyrazol-3-yl]carbamate Chemical compound C=1C=CC=CC=1N1N=C(C2=CN(C)C(=O)C=C2)C(C)=C1NC(=O)OC1=CC=CC=C1 GBVSBTLEIACECG-UHFFFAOYSA-N 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 125000002098 pyridazinyl group Chemical group 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 229910052701 rubidium Inorganic materials 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 235000017557 sodium bicarbonate Nutrition 0.000 description 3
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 229960003787 sorafenib Drugs 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• OQKMVLIVAWGYRD-QWHCGFSZSA-N tert-butyl n-[(3s,4r)-4-phenylpyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CNC[C@H]1C1=CC=CC=C1 OQKMVLIVAWGYRD-QWHCGFSZSA-N 0.000 description 3
• 125000000335 thiazolyl group Chemical group 0.000 description 3
• 125000001544 thienyl group Chemical group 0.000 description 3
• 229960004066 trametinib Drugs 0.000 description 3
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 3
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
• 229960003862 vemurafenib Drugs 0.000 description 3
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 3
• PDIBCWHTVSRHEN-QWHCGFSZSA-N (3R,4S)-3-(4-chlorophenyl)-1-(2-methoxyethyl)-4-nitropyrrolidine Chemical compound ClC1=CC=C(C=C1)[C@@H]1CN(C[C@H]1[N+](=O)[O-])CCOC PDIBCWHTVSRHEN-QWHCGFSZSA-N 0.000 description 2
• AVGXWVJGZDJWIA-CQSOCPNPSA-N (3S,4R)-1-(2-methoxyethyl)-4-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine dihydrochloride Chemical compound Cl.Cl.COCCN1C[C@@H](N)[C@@H](C1)C1=CC(=CC=C1)C(F)(F)F AVGXWVJGZDJWIA-CQSOCPNPSA-N 0.000 description 2
• BVUNFAAOQWGVQX-SJORKVTESA-N (3r,4s)-1-benzyl-3-nitro-4-phenylpyrrolidine Chemical compound C([C@@H]([C@H](C1)C=2C=CC=CC=2)[N+](=O)[O-])N1CC1=CC=CC=C1 BVUNFAAOQWGVQX-SJORKVTESA-N 0.000 description 2
• NUAVFZXWZMQMIP-JHEYCYPBSA-N (3s,4r)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC(F)=CC(F)=C1 NUAVFZXWZMQMIP-JHEYCYPBSA-N 0.000 description 2
• IXGQUXCUXKOKND-QWHCGFSZSA-N (3s,4r)-4-(4-chlorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=C(Cl)C=C1 IXGQUXCUXKOKND-QWHCGFSZSA-N 0.000 description 2
• WYEZQPWAQLECQX-HBMCJLEFSA-N (4r)-3-[(3s,4r)-1-(2-methoxyethyl)-4-phenylpyrrolidine-3-carbonyl]-4-phenyl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](CN(C2)CCOC)C(=O)N2C(OC[C@H]2C=2C=CC=CC=2)=O)=CC=CC=C1 WYEZQPWAQLECQX-HBMCJLEFSA-N 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 2
• GJDARGGNKJXLBC-UHFFFAOYSA-N 1-(5-amino-4-methyl-1-phenylpyrazol-3-yl)ethanone Chemical compound NC1=C(C)C(C(=O)C)=NN1C1=CC=CC=C1 GJDARGGNKJXLBC-UHFFFAOYSA-N 0.000 description 2
• GKAUSTAEDXFJCT-SIKLNZKXSA-N 1-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-(4-methyl-5-methylsulfonyl-2-phenylpyrazol-3-yl)urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(S(C)(=O)=O)=NN1C1=CC=CC=C1 GKAUSTAEDXFJCT-SIKLNZKXSA-N 0.000 description 2
• WQPRCYVUHUSLFA-RPLLCQBOSA-N 1-[5-[2-(cyclopropylamino)pyrimidin-5-yl]-4-methyl-2-phenylpyrazol-3-yl]-3-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C=NC(NC3CC3)=NC=2)=NN1C1=CC=CC=C1 WQPRCYVUHUSLFA-RPLLCQBOSA-N 0.000 description 2
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
• BEBAVVKEBVLKBH-GXTWGEPZSA-N 2-fluoro-5-[(3r,4s)-1-(2-methoxyethyl)-4-nitropyrrolidin-3-yl]benzonitrile Chemical compound [O-][N+](=O)[C@@H]1CN(CCOC)C[C@H]1C1=CC=C(F)C(C#N)=C1 BEBAVVKEBVLKBH-GXTWGEPZSA-N 0.000 description 2
• MQXGRLLKUKVNSU-ONEGZZNKSA-N 2-fluoro-5-[(e)-2-nitroethenyl]benzonitrile Chemical compound [O-][N+](=O)\C=C\C1=CC=C(F)C(C#N)=C1 MQXGRLLKUKVNSU-ONEGZZNKSA-N 0.000 description 2
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
• HCWFKVHARKTZKK-UHFFFAOYSA-N 2-methoxy-n-(trimethylsilylmethyl)ethanamine Chemical compound COCCNC[Si](C)(C)C HCWFKVHARKTZKK-UHFFFAOYSA-N 0.000 description 2
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 2
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 2
• RIARAGIYISCOJY-UONOGXRCSA-N 3-[(3r,4s)-4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl]-5-fluorobenzonitrile Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC(F)=CC(C#N)=C1 RIARAGIYISCOJY-UONOGXRCSA-N 0.000 description 2
• MJDZWYNXMPFSJE-UHFFFAOYSA-N 3-fluoro-5-formylbenzonitrile Chemical compound FC1=CC(C=O)=CC(C#N)=C1 MJDZWYNXMPFSJE-UHFFFAOYSA-N 0.000 description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• GHQFFYOICJWMMA-UHFFFAOYSA-N 5-(2-methoxypyrimidin-5-yl)-4-methyl-2-phenylpyrazol-3-amine Chemical compound C1=NC(OC)=NC=C1C1=NN(C=2C=CC=CC=2)C(N)=C1C GHQFFYOICJWMMA-UHFFFAOYSA-N 0.000 description 2
• MMDSDLIMYXFOHZ-UHFFFAOYSA-N 5-amino-4-methyl-1-phenylpyrazole-3-carboxylic acid Chemical compound N1=C(C(O)=O)C(C)=C(N)N1C1=CC=CC=C1 MMDSDLIMYXFOHZ-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• 239000012099 Alexa Fluor family Substances 0.000 description 2
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
• 239000005695 Ammonium acetate Substances 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 102100032312 Brevican core protein Human genes 0.000 description 2
• 229910000906 Bronze Inorganic materials 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 2
• 101001028827 Homo sapiens Myosin phosphatase Rho-interacting protein Proteins 0.000 description 2
• 102000042838 JAK family Human genes 0.000 description 2
• 108091082332 JAK family Proteins 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
• 239000002138 L01XE21 - Regorafenib Substances 0.000 description 2
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
• UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 230000037364 MAPK/ERK pathway Effects 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 102100037183 Myosin phosphatase Rho-interacting protein Human genes 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• FPTMLGZAIWQCPC-DLBZAZTESA-N N-[(3S,4R)-1-benzyl-4-phenylpyrrolidin-3-yl]-2,2,2-trifluoroacetamide Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@@H](C1)C1=CC=CC=C1)NC(C(F)(F)F)=O FPTMLGZAIWQCPC-DLBZAZTESA-N 0.000 description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
• 101150117329 NTRK3 gene Proteins 0.000 description 2
• 102100035414 Neurofascin Human genes 0.000 description 2
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
• 101150056950 Ntrk2 gene Proteins 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
• 239000004012 Tofacitinib Substances 0.000 description 2
• 241000223109 Trypanosoma cruzi Species 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 229960002964 adalimumab Drugs 0.000 description 2
• 229960002833 aflibercept Drugs 0.000 description 2
• 108010081667 aflibercept Proteins 0.000 description 2
• 125000006241 alcohol protecting group Chemical group 0.000 description 2
• 229960005310 aldesleukin Drugs 0.000 description 2
• 108700025316 aldesleukin Proteins 0.000 description 2
• 125000006242 amine protecting group Chemical group 0.000 description 2
• 235000019257 ammonium acetate Nutrition 0.000 description 2
• 229940043376 ammonium acetate Drugs 0.000 description 2
• 235000019270 ammonium chloride Nutrition 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
• 229960002594 arsenic trioxide Drugs 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 230000027455 binding Effects 0.000 description 2
• 239000012455 biphasic mixture Substances 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 230000010072 bone remodeling Effects 0.000 description 2
• 230000008416 bone turnover Effects 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 239000010974 bronze Substances 0.000 description 2
• BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 2
• 229960001573 cabazitaxel Drugs 0.000 description 2
• 229960001292 cabozantinib Drugs 0.000 description 2
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 229960004117 capecitabine Drugs 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 229960004562 carboplatin Drugs 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 229960003115 certolizumab pegol Drugs 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 229940090100 cimzia Drugs 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 2
• 229960005061 crizotinib Drugs 0.000 description 2
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 229960003901 dacarbazine Drugs 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 229960003668 docetaxel Drugs 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 229940073621 enbrel Drugs 0.000 description 2
• 229960001433 erlotinib Drugs 0.000 description 2
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
• 229960000403 etanercept Drugs 0.000 description 2
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 229960005167 everolimus Drugs 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 239000004052 folic acid antagonist Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 229960002584 gefitinib Drugs 0.000 description 2
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 229960001743 golimumab Drugs 0.000 description 2
• 229940048921 humira Drugs 0.000 description 2
• 150000003840 hydrochlorides Chemical class 0.000 description 2
• 229960002411 imatinib Drugs 0.000 description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 229960000598 infliximab Drugs 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229960005386 ipilimumab Drugs 0.000 description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
• 229960004768 irinotecan Drugs 0.000 description 2
• 229960004891 lapatinib Drugs 0.000 description 2
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
• 229950001845 lestaurtinib Drugs 0.000 description 2
• 229960002247 lomustine Drugs 0.000 description 2
• 201000005296 lung carcinoma Diseases 0.000 description 2
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 229950008814 momelotinib Drugs 0.000 description 2
• ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 2
• 229960001346 nilotinib Drugs 0.000 description 2
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
• 229960003301 nivolumab Drugs 0.000 description 2
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
• 239000010502 orange oil Substances 0.000 description 2
• 210000000963 osteoblast Anatomy 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
• 229960001756 oxaliplatin Drugs 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 229950011410 pacritinib Drugs 0.000 description 2
• HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
• 229960000639 pazopanib Drugs 0.000 description 2
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
• 229960002621 pembrolizumab Drugs 0.000 description 2
• 229960005079 pemetrexed Drugs 0.000 description 2
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
• SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 2
• 229950010632 perifosine Drugs 0.000 description 2
• 229960002087 pertuzumab Drugs 0.000 description 2
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
• HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
• 229940067157 phenylhydrazine Drugs 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• MZVRPCYUUFGMLJ-UHFFFAOYSA-N pyrrolidin-1-ylurea Chemical compound NC(=O)NN1CCCC1 MZVRPCYUUFGMLJ-UHFFFAOYSA-N 0.000 description 2
• 239000000700 radioactive tracer Substances 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 229960004836 regorafenib Drugs 0.000 description 2
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
• 229940116176 remicade Drugs 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
• 229960000215 ruxolitinib Drugs 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 229940068638 simponi Drugs 0.000 description 2
• 229960000714 sipuleucel-t Drugs 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 235000017550 sodium carbonate Nutrition 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 235000010265 sodium sulphite Nutrition 0.000 description 2
• 238000000638 solvent extraction Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 229960004964 temozolomide Drugs 0.000 description 2
• 229960000235 temsirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• WCOFBNUOSFGOPQ-QWHCGFSZSA-N tert-butyl (3R,4S)-3-phenyl-4-[(2,2,2-trifluoroacetyl)amino]pyrrolidine-1-carboxylate Chemical compound C1(=CC=CC=C1)[C@@H]1CN(C[C@H]1NC(C(F)(F)F)=O)C(=O)OC(C)(C)C WCOFBNUOSFGOPQ-QWHCGFSZSA-N 0.000 description 2
• UEGLRNLEEDBVTH-QWHCGFSZSA-N tert-butyl (3s,4r)-3-amino-4-phenylpyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)C[C@@H](N)[C@@H]1C1=CC=CC=C1 UEGLRNLEEDBVTH-QWHCGFSZSA-N 0.000 description 2
• NBHRSXYNDPQZMB-JKSUJKDBSA-N tert-butyl N-[(3S,4R)-1-(2-methoxyethyl)-4-[3-(trifluoromethyl)phenyl]pyrrolidin-3-yl]carbamate Chemical compound COCCN1C[C@@H](NC(=O)OC(C)(C)C)[C@@H](C1)c1cccc(c1)C(F)(F)F NBHRSXYNDPQZMB-JKSUJKDBSA-N 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• LHJIFKOZQQKXJQ-JKSUJKDBSA-N tert-butyl n-[(3s,4r)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl]carbamate Chemical compound C1N(CCOC)C[C@@H](NC(=O)OC(C)(C)C)[C@@H]1C1=CC=CC=C1 LHJIFKOZQQKXJQ-JKSUJKDBSA-N 0.000 description 2
• ZLFBUCKGGYNPOM-QWHCGFSZSA-N tert-butyl n-[(3s,4r)-4-(3-fluorophenyl)pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CNC[C@H]1C1=CC=CC(F)=C1 ZLFBUCKGGYNPOM-QWHCGFSZSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
• 229960001350 tofacitinib Drugs 0.000 description 2
• UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• 102000015533 trkA Receptor Human genes 0.000 description 2
• 108010064884 trkA Receptor Proteins 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
• VTPBKJXRYUDPAJ-UHFFFAOYSA-N (2-ethoxypyrimidin-5-yl)boronic acid Chemical compound CCOC1=NC=C(B(O)O)C=N1 VTPBKJXRYUDPAJ-UHFFFAOYSA-N 0.000 description 1
• YUHZIUAREWNXJT-UHFFFAOYSA-N (2-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=CN=C1F YUHZIUAREWNXJT-UHFFFAOYSA-N 0.000 description 1
• YPWAJLGHACDYQS-UHFFFAOYSA-N (2-methoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C=N1 YPWAJLGHACDYQS-UHFFFAOYSA-N 0.000 description 1
• TWKMYNQPIICYNV-UHFFFAOYSA-N (2-methylpyridin-3-yl)boronic acid Chemical compound CC1=NC=CC=C1B(O)O TWKMYNQPIICYNV-UHFFFAOYSA-N 0.000 description 1
• UFYBTLOLWSABAU-UHFFFAOYSA-N (2-methylpyridin-4-yl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=N1 UFYBTLOLWSABAU-UHFFFAOYSA-N 0.000 description 1
• CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
• CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 1
• NSFIAKFOCAEBER-QZTJIDSGSA-N (2s,3s)-2,3-dihydroxy-2,3-bis(4-methylphenyl)butanedioic acid Chemical class C1=CC(C)=CC=C1[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C1=CC=C(C)C=C1 NSFIAKFOCAEBER-QZTJIDSGSA-N 0.000 description 1
• BUDQKFNVINZMNK-VZCPBZATSA-N (3S,4R)-4-(2,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride Chemical compound Cl.Cl.FC1=C(C=CC(=C1)F)[C@H]1[C@@H](CN(C1)CCOC)N BUDQKFNVINZMNK-VZCPBZATSA-N 0.000 description 1
• FDDATJPEVKESSD-QWHCGFSZSA-N (3s,4r)-1-(2-methoxyethyl)-4-phenylpyrrolidine-3-carboxylic acid Chemical compound C1N(CCOC)C[C@@H](C(O)=O)[C@@H]1C1=CC=CC=C1 FDDATJPEVKESSD-QWHCGFSZSA-N 0.000 description 1
• QQKPLLNPVHZKPU-QWHCGFSZSA-N (3s,4r)-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC(F)=CC(Cl)=C1 QQKPLLNPVHZKPU-QWHCGFSZSA-N 0.000 description 1
• QHGJZOBCYADEOC-QWHCGFSZSA-N (3s,4r)-4-(3-chlorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=CC(Cl)=C1 QHGJZOBCYADEOC-QWHCGFSZSA-N 0.000 description 1
• FQONKHNPTSGQPQ-GXFFZTMASA-N (3s,4r)-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=C(Cl)C(F)=C1 FQONKHNPTSGQPQ-GXFFZTMASA-N 0.000 description 1
• NUEZBHVIYDLJLN-CQSOCPNPSA-N (3s,4r)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=C(F)C=C1 NUEZBHVIYDLJLN-CQSOCPNPSA-N 0.000 description 1
• ISDFOFZTZUILPE-UHFFFAOYSA-N (5-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CN=CC(B(O)O)=C1 ISDFOFZTZUILPE-UHFFFAOYSA-N 0.000 description 1
• REONQWGHSQHTAC-UHFFFAOYSA-N (5-methylpyridin-3-yl)boronic acid Chemical compound CC1=CN=CC(B(O)O)=C1 REONQWGHSQHTAC-UHFFFAOYSA-N 0.000 description 1
• DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 1
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
• PHIWFMZBVZFEQJ-OWOJBTEDSA-N (e)-3-(3,4,5-trifluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC(F)=C(F)C(F)=C1 PHIWFMZBVZFEQJ-OWOJBTEDSA-N 0.000 description 1
• HLVDWMSYSIMRNI-DUXPYHPUSA-N (e)-3-(3,4-difluorophenyl)prop-2-enoyl chloride Chemical compound FC1=CC=C(\C=C\C(Cl)=O)C=C1F HLVDWMSYSIMRNI-DUXPYHPUSA-N 0.000 description 1
• GLBIKPKWQDIQCJ-ZZXKWVIFSA-N (e)-3-(4-fluorophenyl)prop-2-enoyl chloride Chemical compound FC1=CC=C(\C=C\C(Cl)=O)C=C1 GLBIKPKWQDIQCJ-ZZXKWVIFSA-N 0.000 description 1
• MAUMSNABMVEOGP-UHFFFAOYSA-N (methyl-$l^{2}-azanyl)methane Chemical compound C[N]C MAUMSNABMVEOGP-UHFFFAOYSA-N 0.000 description 1
• PCTZLSCYMRXUGW-UHFFFAOYSA-N 1,1,1,2,2-pentafluorobutane Chemical group [CH2]CC(F)(F)C(F)(F)F PCTZLSCYMRXUGW-UHFFFAOYSA-N 0.000 description 1
• DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
• 150000000094 1,4-dioxanes Chemical class 0.000 description 1
• IUKLNTHZUWBZRJ-NZQKXSOJSA-N 1-(5-acetyl-4-methyl-2-phenylpyrazol-3-yl)-3-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C(C)=O)=NN1C1=CC=CC=C1 IUKLNTHZUWBZRJ-NZQKXSOJSA-N 0.000 description 1
• ANEOJIUIPPUTQX-WIOPSUGQSA-N 1-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(1-methyl-2-oxopyrimidin-5-yl)-2-phenylpyrazol-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C2=CN(C)C(=O)N=C2)=NN1C1=CC=CC=C1 ANEOJIUIPPUTQX-WIOPSUGQSA-N 0.000 description 1
• NTQGPSRRYSMWTO-RPLLCQBOSA-N 1-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(6-methylpyridin-3-yl)-2-phenylpyrazol-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C=NC(C)=CC=2)=NN1C1=CC=CC=C1 NTQGPSRRYSMWTO-RPLLCQBOSA-N 0.000 description 1
• MCIDEPHJYIOTSY-RPLLCQBOSA-N 1-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-(1,5-dimethyl-6-oxopyridin-3-yl)-4-methyl-2-phenylpyrazol-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C2=CN(C)C(=O)C(C)=C2)=NN1C1=CC=CC=C1 MCIDEPHJYIOTSY-RPLLCQBOSA-N 0.000 description 1
• JJHKOIBJUOTVJS-JYFHCDHNSA-N 1-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-(2-ethoxypyrimidin-5-yl)-4-methyl-2-phenylpyrazol-3-yl]urea Chemical compound C1=NC(OCC)=NC=C1C1=NN(C=2C=CC=CC=2)C(NC(=O)N[C@H]2[C@@H](CN(CCOC)C2)C=2C=C(F)C(F)=CC=2)=C1C JJHKOIBJUOTVJS-JYFHCDHNSA-N 0.000 description 1
• ACPZENAXIQTOLJ-WIOPSUGQSA-N 1-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-(2-fluoropyridin-3-yl)-4-methyl-2-phenylpyrazol-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C(=NC=CC=2)F)=NN1C1=CC=CC=C1 ACPZENAXIQTOLJ-WIOPSUGQSA-N 0.000 description 1
• RRKXQRAOXXYMBK-RPLLCQBOSA-N 1-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-(5-methoxypyridin-3-yl)-4-methyl-2-phenylpyrazol-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C=C(OC)C=NC=2)=NN1C1=CC=CC=C1 RRKXQRAOXXYMBK-RPLLCQBOSA-N 0.000 description 1
• AGUFJHVZLHGSIG-JYFHCDHNSA-N 1-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-(6-methoxypyridin-3-yl)-4-methyl-2-phenylpyrazol-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C=NC(OC)=CC=2)=NN1C1=CC=CC=C1 AGUFJHVZLHGSIG-JYFHCDHNSA-N 0.000 description 1
• KFQWLAXYPQROSD-IZZNHLLZSA-N 1-[(3s,4r)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-(2-ethoxypyrimidin-5-yl)-4-methyl-2-phenylpyrazol-3-yl]urea Chemical compound C1=NC(OCC)=NC=C1C1=NN(C=2C=CC=CC=2)C(NC(=O)N[C@H]2[C@@H](CN(CCOC)C2)C=2C=C(F)C=C(F)C=2)=C1C KFQWLAXYPQROSD-IZZNHLLZSA-N 0.000 description 1
• OJEPSMXBXPWTMJ-LOSJGSFVSA-N 1-[(3s,4r)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-(2-methoxypyrimidin-5-yl)-4-methyl-2-phenylpyrazol-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C=C(F)C=1)CCOC)C(=O)NC1=C(C)C(C=2C=NC(OC)=NC=2)=NN1C1=CC=CC=C1 OJEPSMXBXPWTMJ-LOSJGSFVSA-N 0.000 description 1
• PGBJLERRUPSDJC-IZZNHLLZSA-N 1-[(3s,4r)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(2-methylpyrimidin-5-yl)-2-phenylpyrazol-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=CC(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C=NC(C)=NC=2)=NN1C1=CC=CC=C1 PGBJLERRUPSDJC-IZZNHLLZSA-N 0.000 description 1
• GVULIULYZZWSNC-RPLLCQBOSA-N 1-[5-(2-cyclopropylpyrimidin-5-yl)-4-methyl-2-phenylpyrazol-3-yl]-3-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C=NC(=NC=2)C2CC2)=NN1C1=CC=CC=C1 GVULIULYZZWSNC-RPLLCQBOSA-N 0.000 description 1
• POIQVYGUNADDCX-IZZNHLLZSA-N 1-[5-(2-ethoxypyrimidin-5-yl)-4-methyl-2-phenylpyrazol-3-yl]-3-[(3s,4r)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea Chemical compound C1=NC(OCC)=NC=C1C1=NN(C=2C=CC=CC=2)C(NC(=O)N[C@H]2[C@@H](CN(CCOC)C2)C=2C=CC(F)=CC=2)=C1C POIQVYGUNADDCX-IZZNHLLZSA-N 0.000 description 1
• CILRFSDUTLBRRZ-RPLLCQBOSA-N 1-[5-(5-cyanopyridin-3-yl)-4-methyl-2-phenylpyrazol-3-yl]-3-[(3s,4r)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea Chemical compound N([C@@H]1CN(C[C@H]1C=1C=C(F)C(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C=C(C=NC=2)C#N)=NN1C1=CC=CC=C1 CILRFSDUTLBRRZ-RPLLCQBOSA-N 0.000 description 1
• OCRUEGKKAHTPKZ-MBUXBYMASA-N 1-[5-[2-(cyclopropylamino)pyrimidin-5-yl]-4-methyl-2-phenylpyrazol-3-yl]-3-[(3s,4r)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.N([C@@H]1CN(C[C@H]1C=1C=CC(F)=CC=1)CCOC)C(=O)NC1=C(C)C(C=2C=NC(NC3CC3)=NC=2)=NN1C1=CC=CC=C1 OCRUEGKKAHTPKZ-MBUXBYMASA-N 0.000 description 1
• GLJATYFHELDGEA-AATRIKPKSA-N 1-chloro-4-[(e)-2-nitroethenyl]benzene Chemical compound [O-][N+](=O)\C=C\C1=CC=C(Cl)C=C1 GLJATYFHELDGEA-AATRIKPKSA-N 0.000 description 1
• IJUNZKOKAXJGRQ-UHFFFAOYSA-N 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-one Chemical compound C1=CC(=O)N(C)C=C1B1OC(C)(C)C(C)(C)O1 IJUNZKOKAXJGRQ-UHFFFAOYSA-N 0.000 description 1
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
• JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
• 125000004463 2,4-dimethyl-thiazol-5-yl group Chemical group CC=1SC(=C(N1)C)* 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
• DVGWUOHIWJBHKY-UHFFFAOYSA-N 2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=C(C2CC2)N=C1 DVGWUOHIWJBHKY-UHFFFAOYSA-N 0.000 description 1
• MOFRJTLODZILCR-UHFFFAOYSA-N 2-fluoro-5-formylbenzonitrile Chemical compound FC1=CC=C(C=O)C=C1C#N MOFRJTLODZILCR-UHFFFAOYSA-N 0.000 description 1
• ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
• 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
• 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
• 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
• COBZMDPXIDGRHY-UHFFFAOYSA-N 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound C1=NC(C)=NC=C1B1OC(C)(C)C(C)(C)O1 COBZMDPXIDGRHY-UHFFFAOYSA-N 0.000 description 1
• SOZKIOYKGZPDKP-UHFFFAOYSA-N 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridazin-3-one Chemical compound C1=CC(=O)N(C)N=C1B1OC(C)(C)C(C)(C)O1 SOZKIOYKGZPDKP-UHFFFAOYSA-N 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• UCZZFMRYPYAGQV-UONOGXRCSA-N 3-[(3r,4s)-4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl]benzonitrile Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=CC(C#N)=C1 UCZZFMRYPYAGQV-UONOGXRCSA-N 0.000 description 1
• IADLVSLZPQYXIF-UHFFFAOYSA-N 3-bromo-5-fluorobenzonitrile Chemical compound FC1=CC(Br)=CC(C#N)=C1 IADLVSLZPQYXIF-UHFFFAOYSA-N 0.000 description 1
• HGZJJKZPPMFIBU-UHFFFAOYSA-N 3-formylbenzonitrile Chemical compound O=CC1=CC=CC(C#N)=C1 HGZJJKZPPMFIBU-UHFFFAOYSA-N 0.000 description 1
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
• 108020004021 3-ketosteroid receptors Proteins 0.000 description 1
• 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
• 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
• 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
• ZRDHIBWZXWKWLM-UONOGXRCSA-N 4-[(3r,4s)-4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl]benzonitrile Chemical compound C1N(CCOC)C[C@@H](N)[C@@H]1C1=CC=C(C#N)C=C1 ZRDHIBWZXWKWLM-UONOGXRCSA-N 0.000 description 1
• WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 1
• 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
• BOIKCRIMIQAFQJ-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carbonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=CC(C#N)=C1 BOIKCRIMIQAFQJ-UHFFFAOYSA-N 0.000 description 1
• ZKDMBENXMCKUQT-UHFFFAOYSA-N 5-(5-amino-4-methyl-1-phenylpyrazol-3-yl)-1H-pyrimidin-2-one hydrochloride Chemical compound Cl.Cc1c(N)n(nc1-c1cnc(=O)[nH]c1)-c1ccccc1 ZKDMBENXMCKUQT-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 101710140080 Brevican core protein Proteins 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• 206010058019 Cancer Pain Diseases 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
• 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
• 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• 206010056740 Genital discharge Diseases 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 101710119866 HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000731086 Homo sapiens Brevican core protein Proteins 0.000 description 1
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 101001023793 Homo sapiens Neurofascin Proteins 0.000 description 1
• 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 1
• 101000800847 Homo sapiens Protein TFG Proteins 0.000 description 1
• 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 108010078049 Interferon alpha-2 Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 239000007993 MOPS buffer Substances 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 108020000002 NR3 subfamily Proteins 0.000 description 1
• 101710189786 Neurofascin Proteins 0.000 description 1
• 102100033857 Neurotrophin-4 Human genes 0.000 description 1
• 239000006057 Non-nutritive feed additive Substances 0.000 description 1
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 102100026531 Prelamin-A/C Human genes 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
• 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 102100033661 Protein TFG Human genes 0.000 description 1
• 108010026552 Proteome Proteins 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 206010041549 Spinal cord compression Diseases 0.000 description 1
• 208000005250 Spontaneous Fractures Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102000005937 Tropomyosin Human genes 0.000 description 1
• 108010030743 Tropomyosin Proteins 0.000 description 1
• 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 229960001686 afatinib Drugs 0.000 description 1
• ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
• 150000008041 alkali metal carbonates Chemical class 0.000 description 1
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 229940076005 apoptosis modulator Drugs 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• GHQPBDDZGPAVJP-UHFFFAOYSA-N azanium;methanol;hydroxide Chemical compound N.O.OC GHQPBDDZGPAVJP-UHFFFAOYSA-N 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• SIISYXWWQBUDOP-UHFFFAOYSA-N bis(1h-imidazol-2-yl)methanethione Chemical compound N=1C=CNC=1C(=S)C1=NC=CN1 SIISYXWWQBUDOP-UHFFFAOYSA-N 0.000 description 1
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 208000024883 bone remodeling disease Diseases 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• OOCUOKHIVGWCTJ-UHFFFAOYSA-N chloromethyl(trimethyl)silane Chemical compound C[Si](C)(C)CCl OOCUOKHIVGWCTJ-UHFFFAOYSA-N 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000012230 colorless oil Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000037011 constitutive activity Effects 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 239000010779 crude oil Substances 0.000 description 1
• 239000004148 curcumin Substances 0.000 description 1
• 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229960002465 dabrafenib Drugs 0.000 description 1
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 229960003914 desipramine Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 229960002866 duloxetine Drugs 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 239000002895 emetic Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• MIHRVXYXORIINI-UHFFFAOYSA-N ethyl 2-cyanopropionate Chemical compound CCOC(=O)C(C)C#N MIHRVXYXORIINI-UHFFFAOYSA-N 0.000 description 1
• UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
• 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 238000002710 external beam radiation therapy Methods 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 201000003911 head and neck carcinoma Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229960003507 interferon alfa-2b Drugs 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 238000010907 mechanical stirring Methods 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229960000600 milnacipran Drugs 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 230000023105 myelination Effects 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
• RPZAAFUKDPKTKP-UHFFFAOYSA-N n-(methoxymethyl)-1-phenyl-n-(trimethylsilylmethyl)methanamine Chemical compound COCN(C[Si](C)(C)C)CC1=CC=CC=C1 RPZAAFUKDPKTKP-UHFFFAOYSA-N 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• QNCUDGRKLRQDMW-UHFFFAOYSA-N n-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C(C=N1)=CN=C1NC1CC1 QNCUDGRKLRQDMW-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 208000019382 nerve compression syndrome Diseases 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
• 229960001158 nortriptyline Drugs 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 230000000010 osteolytic effect Effects 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 238000005191 phase separation Methods 0.000 description 1
• 239000008055 phosphate buffer solution Substances 0.000 description 1
• UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• 235000011181 potassium carbonates Nutrition 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
• 229960001233 pregabalin Drugs 0.000 description 1
• 108010075398 prelamin A Proteins 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
• LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000002462 tachykinin receptor antagonist Substances 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• ZODPLMKUZITHHK-VQTJNVASSA-N tert-butyl N-[(3S,4R)-1-benzyl-4-phenylpyrrolidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(N[C@@H]1CN(C[C@H]1C1=CC=CC=C1)CC1=CC=CC=C1)=O ZODPLMKUZITHHK-VQTJNVASSA-N 0.000 description 1
• RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
• KYXQJIRLQNFANS-WCQYABFASA-N tert-butyl n-[(3s,4r)-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CNC[C@H]1C1=CC=C(F)C=C1F KYXQJIRLQNFANS-WCQYABFASA-N 0.000 description 1
• ZCBPLCRFBQFYKC-WCQYABFASA-N tert-butyl n-[(3s,4r)-4-(2,5-difluorophenyl)pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CNC[C@H]1C1=CC(F)=CC=C1F ZCBPLCRFBQFYKC-WCQYABFASA-N 0.000 description 1
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
• 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
• 235000019798 tripotassium phosphate Nutrition 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000003828 vacuum filtration Methods 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 229960004688 venlafaxine Drugs 0.000 description 1
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• PIAOLBVUVDXHHL-VOTSOKGWSA-N β-nitrostyrene Chemical compound [O-][N+](=O)\C=C\C1=CC=CC=C1 PIAOLBVUVDXHHL-VOTSOKGWSA-N 0.000 description 1